Evidence map›Paper›PMID 40615733›Full record

ArticleJournal of molecular histology2025

Bergenin exerts anti-cancer activity in hepatocellular carcinoma via the PI3K/Akt/mTOR and MAPK/ERK pathways.

Guangrui Lu, Xun Zhuang, Chunrong Wang, Zhenghui Ge, Mengjie Wu, Mengjiao Chen, Zhen Chen, Jianghong Hu, Haoqing Zhai

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Guangrui LuDepartment of Hepatobiliary Pancreatic Surgery, The First College of Clinical Medical Science, Yichang Central People's Hospital, China Three Gorges University, Yichang, 443100, People's Republic of China.
Xun ZhuangDepartment of Gastroenterology, The People's Hospital of Dan Yang, Dan Yang, 212300, Jiangsu, People's Republic of China.
Chunrong WangDepartment of Gastroenterology, The People's Hospital of Dan Yang, Dan Yang, 212300, Jiangsu, People's Republic of China.
Zhenghui GeDepartment of Gastroenterology, The People's Hospital of Dan Yang, Dan Yang, 212300, Jiangsu, People's Republic of China.
Mengjie WuDepartment of Gastroenterology, The People's Hospital of Dan Yang, Dan Yang, 212300, Jiangsu, People's Republic of China.
Mengjiao ChenDepartment of Gastroenterology, The People's Hospital of Dan Yang, Dan Yang, 212300, Jiangsu, People's Republic of China.
Zhen ChenDepartment of Emergency, Tongji Medical College, The Central Hospital of Wuhan, Huazhong University of Science and Technology, Wuhan, 430000, Hubei, People's Republic of China.
Jianghong HuDepartment of Gastroenterology, The People's Hospital of Dan Yang, Dan Yang, 212300, Jiangsu, People's Republic of China.
Haoqing ZhaiDepartment of Oncology Hematology, Qianjiang Central Hospital, Qianjiang, 433100, Hubei, People's Republic of China. haoqingDR@hotmail.com.

Funding

Natural Science Fund of Hubei Science and Technology Department, General Project 2022CFCO02
6 · The paper itself

Abstract

objectiveHepatocellular carcinoma (HCC) remains a therapeutic challenge with limited treatment options. This study investigated the anti-tumor potential of bergenin, a bioactive acylated iridoid glycoside, against HCC and elucidated its underlying molecular mechanisms.

methodsWe systematically evaluated bergenin's effects using: (1) in vitro functional assays including CCK-8 viability, colony formation, TUNEL, flow cytometry, wound healing, and transwell assays; (2) molecular analyses of apoptosis markers (cleaved caspase-3/-9), metastasis-related proteins (MMP-2/-9), and key signaling pathways; and (3) in vivo xenograft models assessing tumor growth inhibition.

resultsBergenin demonstrated potent anti-HCC activity through multiple mechanisms: (1) dose-dependently inhibiting cell proliferation and colony formation; (2) inducing apoptosis via caspase-3/-9 activation; (3) suppressing migration and invasion through MMP-2/-9 downregulation; and (4) significantly inhibiting tumor growth in vivo. Mechanistically, bergenin concurrently inhibited both PI3K/Akt/mTOR and MAPK/ERK signaling pathways in vitro and in vivo.

conclusionOur findings demonstrate that bergenin exerts anti-HCC effects by simultaneously targeting proliferation, apoptosis, and metastasis through dual inhibition of oncogenic PI3K/Akt/mTOR and MAPK/ERK pathways.

Indexed as

Antineoplastic AgentsBenzopyransCarcinoma, HepatocellularLiver NeoplasmsMAP Kinase Signaling SystemPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionTOR Serine-Threonine KinasesAnimalsApoptosisCell Line, TumorCell MovementCell ProliferationHumansMiceAntineoplastic AgentsBenzopyransbergeninMTOR protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesBergeninERKHepatocellular carcinomaMigrationPI3KProliferation

Identifiers

PMID40615733

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.